How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison

Aim: To conduct indirect treatment comparisons between risdiplam and other approved treatments for spinal muscular atrophy (SMA). Patients & methods: Individual patient data from risdiplam trials were compared with aggregated data from published studies of nusinersen and onasemnogene abeparvovec, accounting for heterogeneity across studies. Results: In Type 1 SMA, studies of risdiplam and nusinersen included similar populations. Indirect comparison results found improved survival and motor function with risdiplam versus nusinersen. Comparison with onasemnogene abeparvovec in Type 1 SMA and with nusinersen in Types 2/3 SMA was challenging due to substantial differences in study populations; no concrete conclusions could be drawn from the indirect comparison analyses. Conclusion: Indirect comparisons support risdiplam as a superior alternative to nusinersen in Type 1 SMA. Tweetable abstract How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy? A systematic literature review and indirect treatment comparison.

Automated summary

Indirect comparisons indicate that risdiplam is superior to nusinersen in terms of improved survival and motor function in Type 1 SMA. However, concrete conclusions couldn't be drawn due to substantial differences in study populations for comparisons with onasemnogene abeparvovec in Type 1 SMA and nusinersen in Types 2/3 SMA.